Featured
Media Highlight
•
•
Jun 24, 2026
•
Jun 24, 2026
Eli Lilly dives into hair loss treatments with investment in AI startup Absci
Read at : STAT →
Media Highlight
•
•
Mar 24, 2026
•
Mar 24, 2026
The Most Innovative Biotech Companies of 2026
Read at: Fast Company →ON LINKEDIN
Absci Founder and CEO Sean McClain has had a front-row seat driving the transformation of biotech. In his latest TEDx talk, Sean breaks down how the intersection of AI and biology is shifting human health and revolutionizing how science tackles disease treatment. "I thought the big idea was AI drug discovery, and that's really impactful. But as we dug deeper, we actually saw something extraordinary—that there was even a bigger idea out there. We look at diseases through the lens of chemical imbalance, biological pathways that can be turned on and off, but if you look through a slightly different lens—a physics-based lens, a first-principles lens—you actually realize that most diseases trace back to energy and balances." Watch the full talk, 'Can We Flip the Body's Regenerative Switch?', to explore Sean’s bold vision and see how Absci harnesses generative AI to engineer the future of regenerative biology. 📌Full video: https://lnkd.in/ez38WpZq
Absci Founder and CEO Sean McClain has had a front-row seat driving the transformation of biotech. In his latest TEDx talk, Sean breaks down how the intersection of AI and biology is shifting human health and revolutionizing how science tackles disease treatment. "What if you could take the energy that goes into degeneration—think autoimmune diseases, where the body attacks itself—and flip the switch to redirect or reallocate that energy into regeneration, where the body can heal itself?" In his talk, "Can We Flip the Body's Regenerative Switch?" Sean discusses how the human body operates on a fixed energy budget, and how generative AI can design therapeutics that hold the key to redirecting that energy toward regenerative biology. 📌Watch the full TEDx talk here: https://lnkd.in/ez38WpZq
We’re expanding our clinical team! Momentum is building as our AI-designed biologic ABS-201 rapidly advances in phase 1/2a clinical trials for androgenetic alopecia and endometriosis. To support this next phase, we're looking for leaders with deep expertise in clinical trial operations and drug development programs—including a background backed by advanced degree (PhD, MD, PharmD, MSc) and/or proven, hands-on leadership experience driving successful trials. Join us in shaping the future of AI-driven therapeutics. 🔬 VP of Clinical Development 🔬 Senior Clinical Trial Manager Apply today: https://lnkd.in/e-q5D6ep
All news
